Peter Schirmacher

The 2019 WHO classification of tumours of the digestive system

Irıs D. Nagtegaal, Robert D. Odze, David S. Klimstra et al. · Histopathology · 2019 · 4.1K citations · Full text

Medicine, Oncology, Pathology +17

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

Tae-Won Kang, Tetyana Yevsa, Norman Woller et al. · Nature · 2011 · 1.6K citations

Medicine, Cell Biology, Oncology +16

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel, Andrés Cervantes, Ian Chau et al. · Annals of Oncology · 2018 · 1.1K citations · Full text

Medicine, Oncology, Surgery +14

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 739 citations

Medicine, Oncology, Pharmacology +16